Skip to content
CancerIndex

Publication

Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.

Jade Alvarez, Pola Olczak, Hua-Ling Tsai, Jasmine Terrell, Margaret Wong, Hannah Tsingine, Vikrant Palande, Jeanette Prangsgaard, Emma Huus, Martin Műller, John Dirk Vestergaard Nieland, Richard B S Roden

Journal of virologySep 22, 2026PMID 42627231doi:10.1128/jvi.00448-26 PMC13595945Clinical Trial, Phase IJournal ArticleRandomized Controlled TrialpubmedProvenance
Source
PubMed
Retrieved
Sep 28, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260928-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

A phase I study was conducted in 20 healthy subjects with 20 µg adeno-associated virus 2 (AAV2)-like particles displaying L2 residues 17-36 of both human papillomavirus (HPV) type 16 and HPV31 (AAVLP-HPV) or placebo. AAVLP-HPV vaccination was well tolerated and induced a modest L2-specific serum…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Registered trialsNCT03929172

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.